# Medicenna Therapeutics Corp. (MDNA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/MDNA
## Company Profile
- Ticker: MDNA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Canada
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: Not available
- Market cap: Not available
## Business Overview
### IL-2 Superkine Platform
Medicenna Therapeutics develops engineered cytokines and fusion proteins intended to improve antitumor immune activity. Its Superkine platform modifies cytokine receptor selectivity, potency and pharmacology.
### MDNA11
MDNA11 is a long-acting beta-only IL-2 agonist in the Phase 1/2 ABILITY-1 study. It is being evaluated alone and with pembrolizumab across solid tumors, including new cohorts in non-small cell lung and colorectal cancers.
### Neoadjuvant Melanoma
The investigator-sponsored NEO-CYT study evaluates MDNA11 with nivolumab, with or without ipilimumab, before surgery for melanoma. This setting tests whether IL-2 pathway stimulation can deepen pathologic responses while the tumor remains present.
### MDNA113
MDNA113 is a bifunctional anti-PD-1 and IL-2 Superkine advancing through IND-enabling studies. It is designed to combine checkpoint targeting with localized cytokine activity in one molecule.
### Bizaxofusp
Bizaxofusp, formerly MDNA55, is a Phase 3-ready targeted fusion toxin for recurrent glioblastoma. Medicenna is seeking a strategic partner to advance the program into registrational development.
## Why The Stock Is Moving

Current closing-price context is not available for MDNA.

## Future Catalysts

- Start of NEO-CYT enrollment planned in the first half of 2026, with interim melanoma data expected in the second half.
- Updated ABILITY-1 data expected in the second half of 2026.
- Completion of ABILITY-1 expansion enrollment and an end-of-Phase 1 FDA meeting to define potential registrational trials.
- MDNA113 IND submission and first-in-human trial initiation planned in the second half of 2026.

## Recent News
- 2026-06-26 12:45 EST — [Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights](https://biopharmsignal.com/news/MDNA/medicenna-therapeutics-reports-fiscal-year-2026-financial-results-and-operationa-270c22c3) — Source: Medicenna Therapeutics Corp.
- 2026-06-11 11:00 EST — [Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms](https://biopharmsignal.com/news/MDNA/medicenna-strengthens-u-s-patent-estate-with-newly-issued-and-allowed-patents-ac-c3f9e8a7) — Source: Medicenna Therapeutics Corp.
- 2026-06-03 11:00 EST — [Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026](https://biopharmsignal.com/news/MDNA/medicenna-s-mdna11-potential-in-earlier-line-melanoma-setting-highlighted-in-presentation-of-the-neo-cyt-trial-at-asco-2026) — Source: Medicenna Therapeutics Corp.
- 2026-05-28 13:10 EST — [Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs](https://biopharmsignal.com/news/MDNA/medicenna-announces-closing-of-public-offering-of-units-raising-cdn-4-44-million-to-support-lead-programs) — Source: Medicenna Therapeutics Corp.
- 2026-05-22 11:00 EST — [Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet](https://biopharmsignal.com/news/MDNA/medicenna-announces-the-filing-of-its-prospectus-supplement-and-investment-term-sheet) — Source: Medicenna Therapeutics Corp.